Quectel Unveils a Series of New High Performing 5G, GNSS and 5-in-1 Combo Antennas
27.3.2024 16:00:00 EET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has made further additions to its comprehensive range of antennas for IoT devices and deployments. The latest launches include the YEMN016AA and YEMN017AA 5G 5-in-1 combination antennas, the YECN001J1A and YECT000WBA external 5G antennas and the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas.
“We are thrilled to expand our product line with antennas that offer superior performance and meet the unique needs of our IoT customers,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Quectel consistently enhances its diverse portfolio to precisely address the unique requirements of our clients' deployments and applications, offering unparalleled performance and adaptability, and these antennas add to that portfolio.”
The YEMN016AA is a 5G and global navigation satellite systems (GNSS) 5-in-1 antenna measuring 204.4mm x 86.7mm x 32mm. This ultra-wide-band 5G/4G antenna provides broad coverage from 600–6,000MHz whilst offering backward-compatibility to support 3G and 2G networks as well as LTE Cat-M and narrowband IoT (NB-IoT). The antenna is available with connection via five cable lengths from 300–5,000 mm, terminated with SMA connectors. This low profile, screw mount omnidirectional antenna, ideal for applications where the antenna is required to be discrete, is easy to install with maximum durability assured thanks to its IP69K PC KIBILAC® ASA enclosure. It is compatible with Quectel's RM520x Series modules.
The Quectel YEMN017AA is a 5G screw mount 5-in-1 antenna puck optimized for 5G and 4G networks. With a diameter of 103.5mm and height of 42.5mm, the antenna can integrate a variety of antennas, such as 5G, 4G, GNSS and Wi-Fi antennas. Available with multiple mounting options including screw, pole, wall, magnetic, adhesive and others, the antenna box supports multiple connector types and cable lengths and is designed to offer a more flexible and reliable high-performance antenna for outdoor applications.
Quectel has also added the YECN001J1A and YECT000WBA external 5G antennas to its portfolio. Both antennas cover the 5G NR Sub-6 GHz frequency bands and are compatible with 4G, 3G, 2G and LPWA bands. Featuring high efficiency and gain, both offer an ideal omni-directional antenna solution to ensure high-speed data transmission. Ideal for a diversity of wireless communication devices such as routers, outdoor equipment and real-time monitoring equipment, the antennas feature a diameter of 40.6mm and height of 104mm. The antennas are both RoHS and REACH compliant and Quectel offers flexible installation with custom cable length and connector options.
For users prioritizing GNSS, Quectel has introduced the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas. Operating in the 1164-1189MHz and 1559-1606MHz frequency bands these antennas measure 62mm x 56mm x 23mm. The antennas support different installation or connection methods such as screw mount, adhesive mount, magnetic mount, internal cable, and external SMA. Customized connector types and cable lengths are provided according to requirements.
In common with all Quectel antennas, Quectel provides comprehensive antenna design support such as simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. In addition, Quectel antennas can be pre-integrated with Quectel’s vast range of modules.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327795741/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom